Applied Filters
LSIPR 50 2017: Andrea Borucki
Andrea Borucki was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Eduardo Andretto
Eduardo Andretto was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
Case report: diagnostics in Germany
In September 2016, the German Federal Supreme Court decided a patent case that could have a major impact on companies working in the diagnostics field. Joachim Wachenfeld of Vossius & Partner reports.
The road ahead: potential challenges facing CRISPR/Cas patents
Past successes by trailblazers in other biotechnological fields could assist potential patentees navigate legal bumps along the road to IP protection for CRISPR-related inventions, as Patricia Carson and Ashley Ross of Kirkland & Ellis describe.
Aslan: fighting cancer head-on
Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more.
Fertile ground for innovators
Owners of biotech inventions may find Mexico an attractive country in which to apply for patent protection because of its non-restrictive patent law and its practical approach to examination, as Eder Gutiérrez of Clarke Modet & Co outlines.
Raising the plausibility bar
Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.
Plausibility: How much information is enough?
Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the developing challenges facing patentability in the life sciences field.
A vitally important innovative tool
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
Precision medicine: getting patenting spot on
Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson.
